Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.

被引：2
|
作者：
Johnson, Melissa Lynne
Patel, Manish R.
Siu, Lillian L.
Kozloff, Mark
Aljumaily, Raid
Vaishampayan, Ulka N.
Elgadi, Mabrouk M.
Ge, Miaomiao
Duffy, Christine
Graeser, Ralph
Khedkar, Sheetal Vinay
Jones, Suzanne Fields
Burris, Howard A.
机构：
[1] PLLC, Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[2] Sarah Cannon Res Inst, Florida Canc Specialists, Sarasota, FL USA
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Ingalls Mem Hosp, Harvey, IL USA
[5] Oklahoma Univ, Med Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[6] Karmanos Canc Ctr, Detroit, MI USA
[7] Boehringer Ingelheim GmbH & Co KG, Burlington, ON, Canada
[8] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[9] Boehringer Ingelheim Pharma GmbH & Co KG, Rhein, Germany
[10] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 05期
关键词：
D O I：
10.1200/JCO.2018.36.5_suppl.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
212
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I trial of BI 754091, a programmed death receptor 1 (PD-1) inhibitor, in patients with advanced solid tumors
    Johnson, Melissa
    Patel, Manish
    Siu, Lillian
    Aljumaily, Raid
    Kozloff, Mark
    Vaishampayan, Ulka
    Elgadi, Mabrouk
    Ge, Miaomiao
    Duffy, Christine
    Graeser, Ralph
    Buschke, Susanne
    Khedkar, Sheetal
    Jones, Suzanne F.
    Burrisiii, Howard A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours
    Marabelle, A.
    Cassier, P.
    Delord, J-P.
    Jungles, C.
    Champiat, S.
    Vinceneux, A.
    Korakis, I.
    Huhn, R.
    Poirier, N.
    Vasseur, B.
    Kotecki, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.
    Kang, Yoon-Koo
    Yamaguchi, Kensei
    Oh, Do-Youn
    Kondo, Shunsuke
    Kuboki, Yasutoshi
    Morimoto, Manabu
    Hara, Hiroki
    Rha, Sun Young
    Lin, Chia-Chi
    Tachibana, Yoshifumi
    Ge, Miaomiao
    Elgadi, Mabrouk M.
    Kitano, Shigehisa
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
    Kyriakos P. Papadopoulos
    Nehal Lakhani
    Gerald S. Falchook
    Gosia Riley
    Johan Baeck
    Karen S. Brown
    Gilad Gordon
    Lidya Le
    Judy S. Wang
    Cancer Immunology, Immunotherapy, 2021, 70 : 763 - 772
  • [5] Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
    Papadopoulos, Kyriakos P.
    Lakhani, Nehal
    Falchook, Gerald S.
    Riley, Gosia
    Baeck, Johan
    Brown, Karen S.
    Gordon, Gilad
    Le, Lidya
    Wang, Judy S.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 763 - 772
  • [6] A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours
    Delord, Jean-Pierre
    Kotecki, Nuria
    Marabelle, Aurelien
    Vinceneux, Armelle
    Korakis, Iphigenie
    Jungels, Christiane
    Champiat, Stephane
    Huhn, Richard D.
    Poirier, Nicolas
    Costantini, Dominique
    Vasseur, Berangere
    Cassier, Philippe A.
    BLOOD, 2019, 134
  • [7] Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
    Kotecki, N.
    Champiat, S.
    Delord, J-P.
    Vinceneux, A.
    Jungels, C.
    Marabelle, A.
    Korakis, I.
    Wojciekowski, S.
    Block, E.
    Clarke, N.
    Fromond, C.
    Poirier, N.
    Costantini, D.
    Vasseur, B.
    Cassier, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S841 - S842
  • [8] A phase 1 trial of a potent and selective VEGF receptor inhibitor, apatinib, in patients with advanced solid tumors.
    Sharma, Sunil
    Kang, Yoon-Koo
    Weis, John R.
    Gilcrease, Glynn Weldon
    Davidson, Cynthia
    Kingsford, Rachel
    Collett, Joan
    Orgain, Nicole
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Park, Sook Ryun
    Yoo, Hee-Won
    Kim, Sung-Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] A phase I study of JS']JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors.
    Chi, Zhihong
    Tang, Bixia
    Sheng, Xinan
    Si, Lu
    Cui, Chuanliang
    Kong, Yan
    Li, Dan
    Li, Si Ming
    Yan, Xiegiao
    Mao, Li Li
    Lian, Bin
    Bai, Xue
    Wang, Xuan
    Zhou, Li
    Yu, Jiayi
    Xu, Mingli
    Dong, Lihou
    Song, Haifeng
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.
    Xu, Jian-Ming
    Jia, Ru
    Wang, Yan
    Liu, Rongrui
    Zhao, Chuanhua
    Zhou, Hui
    Xu, Linxinyu
    Kong, Xuan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345